GUTS

Announcements

Nothing here yet

Daily updates

• Fractyl Health's Revita Meets Six-Month Co-Primary Endpoint in REMAIN-1 TrialOct 16, 2026

FDA designations

Nothing here yet

News

• Fractyl Health reported positive one-year REVEAL-1 results showing sustained weight maintenance after a single Revita procedureJun 4, 2026
• Fractyl Health receives authorization to begin first-in-human trial of RJVA-001 gene therapy in the NetherlandsMay 11, 2026
• Fractyl Health completed randomization in the REMAIN-1 pivotal cohort evaluating Revita® for post-GLP-1 weight maintenanceFeb 26, 2026
• Fractyl Health reported 6-month REMAIN-1 data showing Revita weight maintenance post-GLP-1Jan 30, 2026
• Fractyl Health reports positive 6-month REVEAL-1 open-label results showing sustained post-GLP-1 weight maintenance after a single Revita® procedureDec 2, 2025